. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Leukemia. 2021 Mar 2;35(9):2592–2601. doi: 10.1038/s41375-021-01183-8

Table 2:

Univariable and Multivariable analyses of PPVMF risk

Variable		N	Univariable HR (95% CI, p-value)	Multivariable HR (95% CI, p-value)
Age (years)		470	1.03 (1.01–1.05, p=0.001)	1.01 (0.99–1.03, p=0.462)
Sex	Male	241	-	-
	Female	229	0.83 (0.56–1.24, p=0.370)	0.70 (0.46–1.07, p=0.102)
Thrombosis history	None	405	-	-
	Present	65	1.67 (0.92–3.02, p=0.093)	1.18 (0.63–2.20, p=0.605)
CV risk factors	None	369	-	-
	Present	102	0.72 (0.43–1.20, p=0.211)	0.81 (0.47–1.38, p=0.437)
Diagnosis date (year)		470	1.12 (1.07–1.16, p<0.001)	1.11 (1.06–1.15, p<0.001)
rIFNα (time on therapy)		470	0.92 (0.88–0.96, p<0.001)	0.91 (0.87–0.95, p<0.001)
HU (time on therapy)		470	0.98 (0.96–1.01, p=0.215)	0.98 (0.95–1.01, p=0.250)
Other (time on therapy)		470	1.00 (0.95–1.05, p=0.979)	0.99 (0.94–1.05, p=0.810)
Marrow fibrosis, grade	0	68	-	-
Marrow fibrosis, grade	>=1	369	1.48 (0.85–2.57, p=0.167)	1.40 (0.76–2.59, p=0.282)
-	NA	33	-	-